Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATP4A | P20648 | 1/20 | 0.40 |
| ▸ | ATP4B | P51164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882095 | 0.81 | BTK (0.48) | MAPK14BTKNPC1ALDH1A1MAPT | |
| SCHEMBL4888503 | 0.81 | BRAF (0.57) | MAPK14 | |
| SCHEMBL5212033 | 0.79 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL1140469 | 0.79 | MAPK14 (0.61) | MAPK14NPSR1 | |
| SCHEMBL4884817 | 0.71 | TEK (0.53) | MAPK14BTK | |
| SCHEMBL4886681 | 0.69 | BRAF (0.56) | MAPK14 | |
| SCHEMBL11403522 | 0.69 | TRPA1 (0.44) | BTKNPC1ALDH1A1TRPA1 | |
| SCHEMBL11403526 | 0.69 | TRPA1 (0.44) | BTKNPC1ALDH1A1TRPA1 | |
| SCHEMBL11406646 | 0.68 | TRPA1 (0.45) | BTKNPC1TRPA1 | |
| SCHEMBL11406650 | 0.68 | TRPA1 (0.45) | BTKNPC1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | MAPK14 153/4885BTK 19/4885NPC1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.